
Opinion|Videos|April 22, 2025
Advancing Retinal Disease Treatment – The Next Generation of Anti-VEGF Therapies
Listen
0:00 / 0:00
Ehsan Rahimy, MD; David G. Miller, MD, and Jordana Fein, MD, discusses how 8 milligram aflibercept and faricimab, newer anti-VEGF therapies for retinal diseases, offer improved durability with comparable safety profiles to existing treatments, allowing less frequent injections while maintaining equivalent vision outcomes.
Advertisement
Episodes in this series

Timecodes:
1:25- Rationale for high dose aflibercept
5:00- PULSAR trial for AMD
12:00- PHOTON trial for DME
16:21- Changing practice patterns
22:29- Faricimab and role of ang-2 inhibition
28:30 Impact of new therapies
Newsletter
Join thousands of clinicians staying current on new therapies, trial data, and expert insights—subscribe to HCPLive today.
SubscribeAdvertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
Sugar-Sweetened Beverages Associated With Increased Gastric Cancer Risk, With Andrew Chan, MD, MPH
2
Metabolic Dysfunction May Explain Sugar-Sweetened Beverage–Gastric Cancer Link, With Andrew Chan, MD, MPH
3
Microneedle Stamp Enters Phase 1 Trial for Peanut Allergy Immunotherapy
4
Ketamine, Psychedelics Share Neuroimmune Signature in TRD
5











































































